Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPROSTADIL vs BIMATOPROST
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular c AMP, and relaxing smooth muscle. It also inhibits platelet aggregation.
Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It binds to prostaglandin F (FP) receptors on ciliary muscle cells and trabecular meshwork cells, increasing uveoscleral outflow and possibly trabecular outflow of aqueous humor, thereby reducing intraocular pressure. It also directly stimulates the prostaglandin FP receptor, leading to increased matrix metalloproteinase activity and remodeling of the extracellular matrix in the ciliary body.
Treatment of erectile dysfunction (intracavernosal injection or urethral suppository),Palliative therapy to maintain patency of ductus arteriosus in neonates with congenital heart defects pending surgery (intravenous infusion)
Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension,Hypotrichosis of the eyelashes (off-label use for eyelash growth promotion)
Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.
One drop of 0.01% or 0.03% ophthalmic solution instilled into the affected eye(s) once daily in the evening.
5-10 minutes; rapidly metabolized in the lungs, clinical effect lasts longer due to continuous infusion.
Terminal half-life: ~45 minutes (intravenous); after topical ocular administration, systemic half-life is similar due to rapid systemic clearance, with clinical effect lasting 24 hours due to ocular tissue binding
Primarily metabolized via oxidation in the lungs, liver, and kidneys. Approximately 80% inactivated by 15-hydroxy dehydrogenase enzyme on first pass through the lungs.
Bimatoprost is rapidly metabolized via hydrolysis to the more active free acid form by esterases in the cornea and plasma. Further metabolism occurs via oxidation, reduction, and conjugation, primarily in the liver. The major enzymes involved are hepatic cytochrome P450 (CYP) isozymes, with CYP2C9 and CYP3A4 contributing to minor oxidative metabolites. The free acid is subsequently glucuronidated.
Primarily via urine (90%) as metabolites; 10% unchanged; minimal fecal excretion.
Renal: <67% (unchanged and metabolites), Biliary/fecal: ~25%
80-90% bound to albumin.
~88% bound to albumin
0.3-0.4 L/kg (large, extensive tissue distribution).
0.3–0.4 L/kg (indicates distribution primarily into extracellular fluid)
IV: 100%; intracavernosal: nearly complete; intra-arterial: high first-pass lung metabolism limits systemic bioavailability.
Topical ocular: low systemic absorption (~50% absorbed into ocular tissues, with negligible systemic bioavailability due to hydrolysis in plasma)
No specific GFR-based dose modifications established; use with caution in renal impairment due to potential for hypotension.
No dose adjustment required for renal impairment; no specific GFR-based guidelines.
No specific Child-Pugh based dose modifications established; use with caution in hepatic impairment due to altered metabolism.
Use with caution in severe hepatic impairment (Child-Pugh class C); no specific dose adjustments established.
For patent ductus arteriosus: initial IV infusion 0.05-0.1 mcg/kg/min; titrate to response; for erectile dysfunction: not typically used in pediatric patients.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at lower end of dosing range (e.g., initial IV bolus 20 mcg) due to increased sensitivity and comorbidity; monitor blood pressure closely.
No specific dose adjustment required; same dosing as adults, but monitor for increased systemic absorption due to age-related ocular surface changes.
None.
None
Risk of priapism (prolonged erection >4 hours) requiring immediate medical attention,Risk of penile fibrosis or angulation with long-term use,Use with caution in patients with bleeding disorders or on anticoagulants due to bleeding risk,Do not use in neonates with respiratory distress syndrome or persistent fetal circulation,Monitor blood pressure during intravenous use due to hypotension risk
May cause gradual, permanent changes to eyelashes (increased length, thickness, pigmentation) and periorbital tissue (darkening and deepening of the upper eyelid sulcus). Increased iris pigmentation (iridal melanocytes) is irreversible. Use with caution in patients with hepatic or renal impairment. Risk of macular edema, particularly in aphakic or pseudophakic patients with a torn posterior lens capsule. May exacerbate uveitis or cystoid macular edema. Contains benzalkonium chloride; avoid in patients with hypersensitivity to this preservative. Discontinue if signs of systemic absorption occur (e.g., flushing, hypotension).
Hypersensitivity to alprostadil,Conditions predisposing to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia),Penile implant or anatomical penis deformity (for erectile dysfunction formulations),Neonates with persistent fetal circulation or respiratory distress syndrome (for intravenous formulation),In women who are pregnant or breastfeeding (not indicated)
Hypersensitivity to bimatoprost or any component of the formulation. Active intraocular inflammation (e.g., uveitis). Macular edema. Caution in patients with hepatic or renal impairment. Relative contraindication in pregnancy (category C) and breastfeeding.
No known food interactions. Grapefruit may increase levels via CYP3A4 inhibition, but clinical significance is low for topical/intracavernosal use.
No significant food interactions. No dietary restrictions are required.
Alprostadil is not indicated for use in pregnancy; systemic exposure poses risk of uterine hyperstimulation and fetal distress. No adequate human studies; animal studies show embryotoxicity. Avoid in pregnancy unless no safer alternative.
Bimatoprost is a prostaglandin analog. Animal studies have shown embryofetal toxicity including skeletal malformations and increased post-implantation loss at doses >30 times the human exposure. There are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out; avoid use in pregnancy unless benefit outweighs risk. First trimester: potential teratogenicity. Second and third trimesters: potential for premature labor or uterine hyperstimulation due to oxytocic effects.
No data on excretion in human milk; M/P ratio unknown. Due to short half-life and local administration, systemic absorption minimal. Use with caution in breastfeeding.
Bimatoprost is excreted in rat milk, but no human data exist. The molecular weight (415.57 Da) suggests possible excretion into human breast milk. The M/P ratio is unknown. Because of the potential for serious adverse reactions in nursing infants, especially from systemic effects of prostaglandin analogs, breastfeeding is not recommended during treatment or for 6 hours after ophthalmic administration.
No established dosing in pregnancy; contraindicated in pregnant women. No dose adjustment data available for pregnant populations.
Pregnancy induces physiological changes (increased plasma volume, renal clearance, and hepatic metabolism) that may reduce systemic drug concentrations. For bimatoprost ophthalmic solution, negligible systemic absorption occurs, so no dose adjustment is required. In case of systemic use, close monitoring and potential dose adjustments based on clinical response are warranted, but specific guidelines are unavailable.
Alprostadil causes vasodilation via c AMP increase; watch for hypotension and priapism. For erectile dysfunction, inject into corpus cavernosum, not dorsal vein. For patent ductus arteriosus, monitor respiratory drive as apnea is common in neonates.
Bimatoprost is a prostaglandin analog used for lowering intraocular pressure (IOP) in open-angle glaucoma or ocular hypertension. It increases uveoscleral outflow. Administer once daily in the evening. Do not exceed once-daily dosing as it may reduce efficacy. Touching the dropper tip to the eye or surrounding structures can contaminate the solution. Remove contact lenses before instillation and wait 15 minutes before reinserting. Common side effects include conjunctival hyperemia, eyelash growth, and periorbital pigmentation. Monitor for cystoid macular edema in aphakic or pseudophakic patients with a torn posterior lens capsule. Use with caution in patients with active intraocular inflammation (e.g., iritis/uveitis).
Seek immediate medical help if erection lasts more than 4 hours.,Do not use if you have a penile implant or conditions like sickle cell disease.,Avoid driving until you know how this medication affects you.,For injection, rotate injection sites and use within 24hrs of opening vial.,Report any signs of infection at injection site.
Use exactly as prescribed; do not use more than once a day.,Apply in the evening to maximize effectiveness.,Wash hands before and after application.,Remove contact lenses before using and wait 15 minutes before reinserting.,Do not let the dropper tip touch your eye or any surface.,If using more than one eye drop, wait at least 5 minutes between applications.,May cause temporary blurred vision; do not drive until vision clears.,May gradually darken eyelid skin and increase eyelash growth; this is reversible upon discontinuation.,Report any eye pain, vision changes, or signs of infection (redness, swelling) to your doctor.,Store at room temperature away from light and moisture.
"Pirfenidone, an antifibrotic agent used for idiopathic pulmonary fibrosis, may reduce the vasodilatory efficacy of alprostadil, a prostaglandin E1 analog. This interaction likely results from pirfenidone-induced downregulation of prostaglandin receptors or modulation of cyclic AMP signaling pathways, leading to diminished smooth muscle relaxation and reduced therapeutic response to alprostadil. Consequently, patients may experience suboptimal vasodilation, potentially compromising treatment for conditions like erectile dysfunction or peripheral arterial disease."
"Concomitant administration of Alprostadil, a vasodilator, and Aminosalicylic acid, a salicylate, may produce additive antiplatelet effects, increasing the risk of bleeding. Alprostadil inhibits platelet aggregation via cAMP elevation, while Aminosalicylic acid inhibits cyclooxygenase, reducing thromboxane A2 synthesis. Clinically, this may result in prolonged bleeding time, easy bruising, or hemorrhage, especially in patients with underlying coagulopathies or those on other anticoagulants."
"Loxoprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins. Alprostadil, a synthetic prostaglandin E1 analog, exerts its therapeutic effects through vasodilation and inhibition of platelet aggregation. The concurrent use of loxoprofen may attenuate the pharmacological activity of alprostadil by diminishing prostaglandin-mediated responses, potentially leading to reduced efficacy in conditions such as erectile dysfunction or peripheral vascular disease."
"Azelastine, an antihistamine, may reduce the intraocular pressure-lowering efficacy of bimatoprost, a prostaglandin analog used for glaucoma. This interaction is postulated to occur via antagonism of the prostaglandin F2α receptor or through pharmacodynamic opposition, as antihistamines can interfere with the outflow enhancement mechanism of bimatoprost. Clinically, this may result in inadequate intraocular pressure control, necessitating dose adjustment or alternative therapy."
"Pirfenidone, an antifibrotic agent, may reduce the ocular hypotensive efficacy of bimatoprost, a prostaglandin analog used for glaucoma. This interaction is postulated to occur via pirfenidone's inhibitory effects on prostaglandin synthesis or signaling pathways, potentially attenuating bimatoprost-mediated enhancement of uveoscleral outflow. Clinically, patients may experience inadequate intraocular pressure (IOP) reduction, increasing the risk of glaucoma progression."
"Eprosartan, an angiotensin II receptor blocker (ARB), reduces blood pressure by inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Bimatoprost, a prostaglandin analog used for glaucoma, lowers intraocular pressure but can also cause systemic vasodilation, potentially leading to additive hypotensive effects. This interaction may result in excessive lowering of blood pressure, particularly in patients with compromised cardiovascular function or those on multiple antihypertensive agents."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPROSTADIL vs BIMATOPROST, answered by our medical review team.
ALPROSTADIL is a Prostaglandin Analog that works by Alprostadil is a synthetic prostaglandin E1 (PGE1) that causes vasodilation by binding to prostanoid EP receptors, increasing intracellular c AMP, and relaxing smooth muscle. It also inhibits platelet aggregation.. BIMATOPROST is a Prostaglandin Analog that works by Bimatoprost is a synthetic prostamide analog that selectively mimics the effects of prostamide F2α. It binds to prostaglandin F (FP) receptors on ciliary muscle cells and trabecular meshwork cells, increasing uveoscleral outflow and possibly trabecular outflow of aqueous humor, thereby reducing intraocular pressure. It also directly stimulates the prostaglandin FP receptor, leading to increased matrix metalloproteinase activity and remodeling of the extracellular matrix in the ciliary body.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPROSTADIL and BIMATOPROST depend on the specific clinical indication. These are both Prostaglandin Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPROSTADIL is: Initial: 20-40 mcg IV bolus over 1-2 seconds; then 30-70 mcg/min continuous IV infusion for erectile dysfunction via intracavernosal injection: 2.5-10 mcg; for patent ductus arteriosus: 0.05-0.1 mcg/kg/min continuous IV infusion.. The standard adult dose of BIMATOPROST is: One drop of 0.01% or 0.03% ophthalmic solution instilled into the affected eye(s) once daily in the evening.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPROSTADIL and BIMATOPROST in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPROSTADIL is classified as Category C. Alprostadil is not indicated for use in pregnancy; systemic exposure poses risk of uterine hyperstimulation and fetal distress. No adequate human studies; animal studies show embry. BIMATOPROST is classified as Category C. Bimatoprost is a prostaglandin analog. Animal studies have shown embryofetal toxicity including skeletal malformations and increased post-implantation loss at doses >30 times the h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.